CN109863175A - 用抗-kir3dl2药剂进行的治疗 - Google Patents

用抗-kir3dl2药剂进行的治疗 Download PDF

Info

Publication number
CN109863175A
CN109863175A CN201780064844.4A CN201780064844A CN109863175A CN 109863175 A CN109863175 A CN 109863175A CN 201780064844 A CN201780064844 A CN 201780064844A CN 109863175 A CN109863175 A CN 109863175A
Authority
CN
China
Prior art keywords
kir3dl2
antibody
cell
medicament
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780064844.4A
Other languages
English (en)
Chinese (zh)
Inventor
卡里纳·帕蒂雷尔
埃莱娜·西卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of CN109863175A publication Critical patent/CN109863175A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780064844.4A 2016-10-21 2017-10-19 用抗-kir3dl2药剂进行的治疗 Pending CN109863175A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410880P 2016-10-21 2016-10-21
US62/410,880 2016-10-21
PCT/EP2017/076751 WO2018073363A1 (en) 2016-10-21 2017-10-19 Treatment with anti-kir3dl2 agents

Publications (1)

Publication Number Publication Date
CN109863175A true CN109863175A (zh) 2019-06-07

Family

ID=60268349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780064844.4A Pending CN109863175A (zh) 2016-10-21 2017-10-19 用抗-kir3dl2药剂进行的治疗

Country Status (8)

Country Link
US (3) US20190248895A1 (https=)
EP (1) EP3529277A1 (https=)
JP (1) JP7676109B2 (https=)
KR (2) KR20230173745A (https=)
CN (1) CN109863175A (https=)
AU (1) AU2017345203B2 (https=)
CA (1) CA3037851A1 (https=)
WO (1) WO2018073363A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729052A (zh) * 2019-10-04 2022-07-08 丹娜法伯癌症研究院 抗kir3dl3抗体和其用途

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US10280222B2 (en) 2014-03-14 2019-05-07 Innate Pharma Humanized antibodies with increased stability
CA3125945A1 (en) * 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640880A (zh) * 2012-09-19 2015-05-20 先天制药公司 Kir3dl2结合剂
WO2015136052A1 (en) * 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability
CN105026427A (zh) * 2013-02-20 2015-11-04 依奈特制药公司 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2002050122A2 (en) 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
ES2393485T3 (es) 2003-07-02 2012-12-21 Innate Pharma Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
SG173322A1 (en) 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
WO2005105848A1 (en) 2004-04-30 2005-11-10 Innate Pharma Compositions and methods for enhancing nk cell activity
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
ATE548389T1 (de) 2004-08-03 2012-03-15 Innate Pharma Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ES2539045T3 (es) 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
US20140234342A1 (en) 2011-06-21 2014-08-21 Innate Pharma Nkp46-mediated nk cell tuning
CA2881764C (en) 2012-09-19 2022-08-16 Innate Pharma Kir3dl2 binding agents
DK2956482T3 (en) 2013-02-14 2017-10-16 Innate Pharma TREATMENT OF PERFECT T cell lymphoma
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
CA2959463A1 (en) 2014-09-16 2016-03-24 Innate Pharma Treatment regimens using anti-nkg2a antibodies
WO2016207278A1 (en) 2015-06-23 2016-12-29 Innate Pharma Multispecific nk engager proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640880A (zh) * 2012-09-19 2015-05-20 先天制药公司 Kir3dl2结合剂
CN105026427A (zh) * 2013-02-20 2015-11-04 依奈特制药公司 特异性结合至kir3dl2的化合物用于治疗外周t细胞淋巴瘤
WO2015136052A1 (en) * 2014-03-14 2015-09-17 Innate Pharma Humanized antibodies with increased stability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INNATE PHARMA: "Checkpoint antibodies in immuno-oncology", 《HTTP://WWW.INNATE-PHARMA.COM/SITES/DEFAULT/FILES/NY_R_DAY_2016-V4.PDF》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114729052A (zh) * 2019-10-04 2022-07-08 丹娜法伯癌症研究院 抗kir3dl3抗体和其用途

Also Published As

Publication number Publication date
KR20190068602A (ko) 2019-06-18
EP3529277A1 (en) 2019-08-28
WO2018073363A1 (en) 2018-04-26
US20210087270A1 (en) 2021-03-25
CA3037851A1 (en) 2018-04-26
JP2020500161A (ja) 2020-01-09
US20240391999A1 (en) 2024-11-28
AU2017345203A1 (en) 2019-05-02
US11970535B2 (en) 2024-04-30
AU2017345203B2 (en) 2024-08-01
KR20230173745A (ko) 2023-12-27
JP7676109B2 (ja) 2025-05-14
US20190248895A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
US12084498B2 (en) Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
AU2015314316B2 (en) Cross reactive Siglec antibodies
US20170233479A1 (en) Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3722314A1 (en) Anti-vista antibodies and fragments
KR20200026254A (ko) 암을 치료하기 위해 인간 siglec-9 에 대한 항체 및 인간 nkg2a 에 대한 항체를 사용하는 조합 치료요법
EP3255062B1 (en) Anti-nkp46 antibody for diganosis of a non-cutaneous peripheral t-cell lymphoma (ptcl)
NO342318B1 (no) Anti-KIR2DL antistoffer og sammensetninger derav.
BR112015006060B1 (pt) Anticorpo monoclonal, composição farmacêutica e uso do anticorpo monoclonal
CN109863175A (zh) 用抗-kir3dl2药剂进行的治疗
WO2008087219A1 (en) Compositions and methods for regulating t cell activity
US12448442B2 (en) Treatment of T cell lymphoma
RU2835929C2 (ru) Лечение т-клеточной лимфомы
HK40037923A (en) Anti-vista antibodies and fragments
HK1195080A (zh) 调节nk细胞活性的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190607

RJ01 Rejection of invention patent application after publication